ERAS-801

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameERAS-801
Drug Alias NameERAS-801JGK-068S
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsGlioblastomaAstrocytoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRegents Of The University Of California
China Registration ClassN/A

Develop Information

Active CompaniesKatmai Pharmaceuticals IncNational Institutes Of HealthUclas Jonsson Comprehensive Cancer Center +[4] 
Inactive CompaniesN/A
Active IndicationsGlioblastomaAstrocytoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A